Genetic Technologies Limited (NASDAQ: GENE) has been making large strides in the area of women’s health recently with the opening of more centers that utilize the BREVAGenplus. Ultimately this will benefit women who are at risk of breast cancer, while allowing the company to turn a healthy profit.

The company announced that two new breast health centers will begin to offer BREVAGenplus to their at-risk patients in a systematic fashion, this will bring the grand total to eight so far. The company expects an additional number of new breast health centers to follow later in calendar year 2015. As a result, the company reiterated that it expects sales growth to accelerate in the second half of the 2015 calendar year and beyond.

For a little background on Genetic Technologies, the company is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women’s health.

By working with these breast health centers and healthcare practitioners, the company has developed a protocol where women who may be at significant risk and have little to no family history of breast cancer, are being screened. Genetic Technologies is instituting pilot programs that create a “safety net” for patients by assessing both hereditary as well as sporadic breast cancer risk.

The adoption of BREVAGenplus by a total of eight new breast health centers validates the company’s recently re-focused sales and marketing strategy, which was announced last September. While these centers are more complex entities with longer sales cycles, they offer higher and more stable long-term revenue potential.

Genetic Technologies is working closely with these centers while also referring healthcare practitioners to ensure the creation of a breast cancer risk assessment approach in which BREVAGenplus plays an integral role. In this way, the company is attempting to reinforce the benefits of the test, ease its adoption by the new clinics, and ensure its routine use by them.

CEO Eutillio Buccilli kept it short and sweet when he commented on the announcement:

This significantly changes the landscape; the paradigm shifts from detection and intervention to risk assessment, prevention and even earlier detection.

Shares of Genetic Technologies were up 27% at $5.39 on a 52-week trading range of $1.04 to $11.00. The stock has a consensus analyst price target of $12.50.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.